Rx License-Rx

DEL05-02

Screening Method and Gene Therapy Approach for Treating Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia (ARVC/D)

An innovative and efficacious treatment targeting the genetic drivers of arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D).

Intelligence Memo

Owner: University-originated technology office

Core category: Research Tools

Therapeutic area: Cardiometabolic

Indication:

Modality: Cell/Gene Therapy

Focus tags: Cardiometabolic

Technology tags: Cell/Gene Therapy

Mechanism:

Development stage: Early / Discovery

Patent status: Needs review

Availability: Available for license

Risk Flags

  • Human validation and clinical path require diligence.
  • Patent scope and remaining exclusivity need review with counsel.
  • Inventor readiness and licensing terms are not yet verified.

Strategic Pharma Attractiveness

Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Cardiometabolic wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.

Most logical pharma targets Roche Diagnostics — Companion diagnostic and translational biomarker fit. Thermo Fisher — Research-tool commercialization and pharma services channels. Illumina / Tempus — Data, sequencing, and clinical decision-support adjacency.

Development Strategy to Increase PoS

First indication: the narrowest patient segment where the mechanism can create a measurable signal quickly

Study design: One decisive preclinical or analytical validation package with a hard go/no-go threshold.

Key experiments Validate the AI-optimized pivot: Start as an orphan, HLA-defined oncology asset with manufacturing outsourced from day zero Run independent replication of the core claim with pre-specified success criteria Generate a partner-facing risk register that separates solved, testable, and unresolved risks

Final Recommendation

Proceed with repositioning: Interesting science, but the next dataset should be funded before committing to a full license. The most investable version is: Start as an orphan, HLA-defined oncology asset with manufacturing outsourced from day zero

Best next experiment: Run the smallest independent study that validates: Use a centralized CDMO, lock the release assay early, and design the first trial around tumor-antigen evidence rather than broad basket ambition.

Best licensing timing: Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.